about
sameAs
Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging fieldAn efficient targeted drug delivery through apotransferrin loaded nanoparticlesEthical issues in nanomedicine: Tempest in a teapot?Clinical Translation of Nanomedicine.The role of philosophy of science in Responsible Research and Innovation (RRI): the case of nanomedicine.Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx® (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague-Dawley rats.Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania.A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies.Responsible conduct in nanomedicine research: environmental concerns beyond the common ruleTargeted polymeric therapeutic nanoparticles: design, development and clinical translationDrug delivery interfaces in the 21st century: from science fiction ideas to viable technologies.Integrated research into the nanoparticle-protein corona: a new focus for safe, sustainable and equitable development of nanomedicines.Theranostic barcoded nanoparticles for personalized cancer medicineMind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Nanoparticles: a promising modality in the treatment of sarcomas.Nanomedicine and ethics: is there anything new or unique?Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives.Liposomes as drug delivery systems for the treatment of TB.Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.Responsible healthcare innovation: anticipatory governance of nanodiagnostics for theranostics medicine.Assessing nanoparticle toxicity in cell-based assays: influence of cell culture parameters and optimized models for bridging the in vitro-in vivo gap.Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery.Drug delivery by supramolecular design.Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer ApplicationsIncreasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.Tiopronin monolayer-protected silver nanoparticles modulate IL-6 secretion mediated by Toll-like receptor ligands.Biological Atomic Force Microscopy for Imaging Gold-Labeled Liposomes on Human Coronary Artery Endothelial Cells.Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin.Naming it 'nano': Expert views on 'nano' terminology in informed consent forms of first-in-human nanomedicine trials.Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles.Nanotechnology in neurosurgery: thinking small, dreaming big.Scientists' perception of ethical issues in nanomedicine: a case study.Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial.Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies.The implications and applications of nanotechnology in dentistry: A review.Social Studies of Nanopharmaceutical Research
P2860
Q26822431-0B3140EB-DEC1-4F8A-BC49-6F40AAE334EDQ28476276-98DB41EB-112E-43A8-868F-F59C2E6669EAQ30276129-0C82A7D0-B362-483D-AFEC-3FF8DE778204Q30355939-B03CD43E-BABC-4B22-AE3C-71A5CF2295C8Q30375791-076CE566-5BF7-4F71-AEB0-777E19AC547AQ33600055-D6DF508A-FD2E-498A-941C-46A5B46FE60BQ33711698-32583F84-229E-4214-B9A6-124EED2D157EQ34207279-613DCDA9-8E70-4845-B365-645E527EBD7EQ36447479-BB0BBAFE-3701-4C76-80F9-CB089611F914Q36740542-BCC310FD-39C8-4AC4-988F-3BDB0CB9E1A8Q36934007-316BFCD6-F47C-41A0-A158-C4F9C836C125Q37283351-5CB81DA5-0F55-4F85-8FD3-F826AA5DD5F2Q37331805-E18449DA-F3F6-424E-BBEA-E14D452E7158Q37414318-D16C6005-C181-4594-BCDD-B78B92F0BAEEQ37467770-21A5E759-63FF-414E-82B9-3A9F6A8B98DCQ37761069-97198CC6-3691-4AA4-A3E5-9636B275EB6EQ37764788-2ACBF7A7-E501-4DBE-AE78-802B269CF93FQ37834336-14400BB5-391C-47A9-ADF9-4E72A5335021Q37949386-4278F4C1-9F12-4184-A644-F3D1AF1F50F8Q37964713-BB345C2C-F093-4DFA-AAAE-F2C2A5FA28D1Q38068224-A45E8F0D-C901-43D3-970E-DBEBC3848C39Q38123394-BAFBA6F7-D8EB-421A-BB12-A82216C10F67Q38151736-5BCC879C-EDCB-4BAD-8596-E5D3EFC450B9Q38638945-D0AE556C-4A21-47EE-8CFE-7938FC654817Q38759181-3B7BADF7-EF2E-463C-B158-BAF2385CA0E7Q39622438-4F89167C-92AB-453C-97C7-8DDFC5E3491DQ39932833-2307DC39-7669-4798-939F-7C84245DC3CAQ40335789-1A2227B1-DFF6-4AF2-89C7-DCA1863E9B20Q42266771-B0D414BF-41E5-4EB1-86AE-12380E236BC4Q42696414-D7DD4CFD-79E0-41EE-A045-345ED34AEC3FQ43230806-F731963B-9176-4DBF-BBF3-A5E1C0BA4D26Q47858629-9A6D191E-D7EC-4942-B0B4-F2E72A36706DQ48141132-881B74BD-DB43-4497-9BB8-4E898F109687Q48616305-E8D06459-71B9-4601-BF9E-C2CE7094A117Q52584444-C8FA4221-3C9A-43A6-BF7D-6E0A566E4F02Q54938534-4910710F-EF51-478A-95F3-E0E57EB4663DQ57915465-DF0AB8E3-2D35-4245-A7E8-F94B95155485
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Ethics in nanomedicine
@ast
Ethics in nanomedicine
@en
Ethics in nanomedicine
@nl
type
label
Ethics in nanomedicine
@ast
Ethics in nanomedicine
@en
Ethics in nanomedicine
@nl
altLabel
Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma.
@en
prefLabel
Ethics in nanomedicine
@ast
Ethics in nanomedicine
@en
Ethics in nanomedicine
@nl
P2093
P2860
P921
P356
P1476
Ethics in nanomedicine
@en
Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma.
@en
P2093
Ashish Udhrain
David B Resnik
Donald W Northfelt
Keith M Skubitz
Sally S Tinkle
P2860
P356
10.2217/17435889.2.3.345
P407
P577
2007-01-01T00:00:00Z
2007-06-01T00:00:00Z